Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

Rhea-AI Summary

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on developing life-saving medicines, has scheduled a conference call and audio webcast for November 7, 2024, at 8:30 a.m. ET. During this event, the company will present its third quarter 2024 financial results and provide a business update. Participants can join via phone at (646) 307-1963 (domestic) or (800) 715-9871 (international) using conference ID 6580777. A live webcast will be available on the company's website, with an archived version accessible approximately two hours after the event.

News Market Reaction – CMRX

+2.06%

+2.06% Session move

In the trading session that priced this news, CMRX gained 2.06%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.

To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time and refer to conference ID 6580777. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant diffuse glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.

CONTACT:

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

When will Chimerix (CMRX) report Q3 2024 earnings?

Chimerix will report its third quarter 2024 financial results on Thursday, November 7, 2024, at 8:30 a.m. ET.

How can I access Chimerix's (CMRX) Q3 2024 earnings call?

You can access the call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) with conference ID 6580777, or via webcast on Chimerix's website.

Where can I find the replay of Chimerix's (CMRX) Q3 2024 earnings webcast?

The archived webcast will be available on the Investors' section of Chimerix's website (www.chimerix.com) approximately two hours after the live event.